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Abstract 
 Cancer patients have a reduced exercise capacity compared to age-matched healthy 
counterparts which contributes to premature fatigue. The reductions in exercise capacity are 
multifactorial and vary depending on the type of treatments and the specific cancer. Given that 
cancer treatments have been shown to impair cardiovascular and/or skeletal muscle function, it is 
difficult to determine if cancer itself reduces exercise capacity. We used a rat prostate tumor 
model to test the hypothesis that cancer independently reduces endurance exercise capacity. 
Methods: In male Copenhagen rats (COP/CrCrl), an initial treadmill test to exhaustion was used 
to determine endurance exercise capacity. Subsequently, the prostates of the rats were injected 
with either prostate carcinoma cells (R-3327 AT-1) in Matrigel (cancer: n = 9) or Matrigel only 
(sham: n = 7). Treadmill tests to exhaustion were repeated four and eight weeks post-surgery. 
Results: Time to exhaustion decreased over the course of the experimental protocol in both the 
sham and cancer groups. However, the overall reduction in time to exhaustion in the cancer 
group (-16.7 ± 1.9 min) was significantly greater (p = 0.038) than the sham group (-10.1 ± 2.2 
min). Despite no differences in total body mass at the end of the experimental protocol, heart, 
left ventricle, and gastrocnemius muscle mass were significantly lower in the cancer group 
compared to the sham group (p < 0.05 for all). Moreover, within the cancer group heart and left 
ventricle mass, but not gastrocnemius mass, were significantly inversely correlated with prostate 
tumor mass. Conclusion: Endurance exercise capacity was reduced in rats with untreated 
prostate cancer to a greater extent than it was reduced in sham operated rats. Although multiple 
mechanisms likely contributed to the reduced exercise capacity, reductions in heart and 
gastrocnemius muscle mass likely played an important role. 
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Chapter 1 - Literature Review 
Prevalence and Impact of Cancer 
 Currently in the United States, over 14 million people have a history of cancer (Miller et 
al., 2016). These children and adults are considered cancer survivors by the American Cancer 
Society. 66.5% of people diagnosed with cancer survive for over five years after diagnosis and 
treatment, with the majority of deaths within this five year span coming from those over 65 years 
in age (Siegel et al., 2016). In 2016 alone it is estimated that there will be 1,685,210 new cancer 
cases, and 595,690 cancer deaths (Siegel et al., 2016). The financial burden of cancer in the U.S. 
in 2012 was over 70 billion USD, which is expected to continue to rise (Lee et al., 2016). 
 For an individual, the cost of cancer is not only the cost of insurance and copays, but time 
away from work for treatment. Because diagnoses are specific and individualized, the exact cost 
per person can vary widely from very little to tens of thousands of dollars. The diagnosis of 
cancer also comes with far more than just a monetary or economic cost; the toll it has on the 
mental health of patients (and caregivers (Padmaja et al., 2016)) can be immense. Fatigue is 
prevalent in cancer survivors and often linked to reduced quality of life, stemming from a 
reliance on caregivers, an inability to maintain employment, and difficulty leading a ‘normal’ life 
(Curt et al., 2000). The increased psychological stress of these fatigue ramifications can lead to 
depression and anxiety (Chipperfield et al., 2013), which can manifest physically with a 
suppressed immune system (Dhabhar, 2014), fatigue, and generally a lower quality of life 
(Chipperfield et al., 2013). Distress and depression are associated with suppressed cytotoxic T-
cell and Natural-Killer-Cell presence, which are associated with immune surveillance of tumors 
(Reiche et al., 2004). This added stress lowers the body’s ability to fight the tumor on its own. 
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Prostate Cancer 
 One in five men will be diagnosed with prostate cancer in his lifetime, making prostate 
cancer the most prevalent cancer in men; in 2016 alone an estimated 180,890 men will be 
diagnosed with prostate cancer (Siegel et al., 2016). The most commonly diagnosed groups are 
men over 50, those of African-American heritage, and those with a family history of the disease 
(Attard et al., 2016).  
 The signs and symptoms of prostate cancer vary depending on the progression of the 
disease and whether or not metastases have developed. In many cases, symptoms involve 
painful, irregular, and/or bloody urination with more advanced cases including pain in the lower 
back, hip, or femur. Each case is different and the disease progresses differently for each person, 
making prostate cancer treatment unique to the patient. 
 
Prostate Cancer Treatment 
 Because the prostate is a sex organ, many prostate carcinomas initially grow in response 
to androgens such as testosterone (Attard et al., 2016; Miller, 2016). Treatment usually includes 
androgen deprivation therapy (ADT) which is accomplished by pharmaceutical reductions in 
androgens using a hormone blocker, or physical castration by removing one or both testicles, or 
removal of the prostate (i.e., radical prostatectomy; Miller et al., 2016). Reducing androgen 
levels in the body elicits several side effects such as erectile dysfunction, loss of libido, 
diminished bone density, loss of skeletal muscle mass, weight gain, insulin resistance, fatigue, 
and depression. Resistance training and aerobic training is often prescribed to combat these side 
effects, especially bone density, muscle mass, and weight gain changes (Mason, 2006).  
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 After reducing the androgen levels in the body, prostate tumors may become ‘castration 
resistant’ where upon continued growth occurs despite little to no androgen content in the body. 
If a prostate tumor becomes castration resistant the treatment option has to change, as lowering 
levels of androgens in the body may no longer be sufficient to combat the disease. However, 
patients often remain on ADT in order to keep the tumor from further progression, and other 
adjuvant treatments with chemotherapy and/or radiation are included (Miller et al., 2016). 
 
Prostate Cancer and Exercise 
 According to the American College of Sports Medicine’s extensive review of cancer and 
exercise (Schmitz et al., 2010), it is safe for individuals with prostate cancer to exercise. Indeed, 
the majority of deaths from prostate cancer do not come directly from the cancer but result from 
cardiovascular disease later in life (Schmitz et al., 2010). Exercise decreases the risk of death 
from cardiovascular disease, as the cardiovascular benefits of exercise are well documented 
(Lavie et al., 2015). In addition, exercise decreases the risk of developing cancer and increases 
survivorship in prostate cancer patients (Antonelli et al., 2009). 
 In preclinical studies during exercise prostate tumor blood flow can increase up to 200% 
when compared to resting conditions in the rat, leading to a 50% reduction in hypoxia within the 
tumor (McCullough et al., 2014). Voluntary wheel running in mice has even been shown to 
decrease the risk of metastasis with a prostate tumor model (Jones et al., 2012). Increasing the 
vascular density, decreasing hypoxia, and increasing apoptosis all act to ‘normalize’ the cell, 
leading to increased chemotherapy delivery and a better outcome (Betof et al., 2015). 
 In human studies of prostate cancer, reductions in maximal oxygen consumption (VO2max) 
are reported in men on ADT for more than three months compared to men on ADT for less than 
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three months (Wall et al., 2015). This study had no healthy age-matched control group, so 
comparisons to the healthy population can not be made. While the authors attribute the reduction 
in exercise capacity to ADT, individuals who have been on ADT longer have also likely had 
prostate cancer longer. 
  In another study of exercise performance of men with prostate cancer, 6-minute walk 
distance and handgrip tests were reduced significantly compared to age-matched healthy controls 
(Alibhai et al., 2015). While there was a prostate cancer group who was not on ADT (prostate 
cancer control group), no statistical comparisons were made with this group against either the 
control or the prostate cancer group on ADT (Alibhai et al., 2015). This study also states that 
individuals on ADT have more aggressive cancer phenotypes, leading to more aggressive 
treatments aside from ADT. While ADT certainly plays a role in the reductions in performance, 
whether or not the cancer itself plays a role has yet to be investigated.  
 
Cancer Cachexia 
 Cachexia is defined as weight loss of at least 5% that is not due to edema, occurring within 
a period of 12 months or less that is due to an underlying disease including cancer (Evans et al., 
2008). Cachexia is experienced by an estimated 50-80% of cancer patients (Argilés et al., 2014) 
and is likely one of the contributing factors involved with the reduction in exercise capacity seen 
in cancer patients (Peel et al., 2014). Along with decreased performance, cancer may cause 
exaggerated fatigue and a lower quality of life (Curt et al., 2000; Cella et al., 2001; Murphy, 
2016). Because exercise seems to improve the tumor microenvironment (McCullough et al., 
2013), finding the cause of this cancer-related fatigue could help to improve outcomes in prostate 
cancer patients. 
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 Markers of muscle atrophy, such as activin A, interleukin-6, tumor necrosis factor-α, and 
forkhead box O pathway (Tsujinaka et al., 1996; Chen et al., 2014; Sandri et al., 2004) are 
upregulated with many cancers, including colon cancer compared to controls leading to 
reductions in gastrocnemius mass (Matsuyama et al., 2015). However, reductions in food intake 
(anorexia) have also been shown with cancers (especially of the digestive system), leading to a 
reduction in body mass and skeletal muscle mass (Springer et al., 2014; Matsuyama et al., 2015). 
These reductions in body and muscle mass are likely due to the cancer itself, but how these affect 
performance has not been investigated.  
 Cardiac cachexia, a loss of cardiac muscle mass due to disease, and cardiac dysfunction are 
evident in many cancer survivors who have been on treatments known for cardiotoxicity (such as 
doxorubicin; Curigliano et al., 2016). These instances of heart disease might not be caused by the 
treatments, they may only be exacerbating already existing heart disease (Murphy, 2016). 
Reductions in heart mass have been shown in colon cancer (Matsuyama et al., 2015), a 
subcutaneous colon cancer model (Wysong et al., 2011) and a liver tumor model (Springer et al., 
2014). Along with reductions in heart mass, Springer et al. (2014) found reductions in stroke 
volume, a measure of cardiac function, when compared to a sham group.  
 There could be differences in how tumors reduce the mass of cardiac skeletal muscle 
(Cosper & Leinwand, 2011), and there are still gaps in knowledge as to how much of an effect 
the cancer itself has on cachexia (Murphy, 2016). Finding mechanisms that contribute to 
reductions in muscle mass could help to combat the effects of the cancer could improve quality 
of life in cancer patients.  
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Experimental Tumor Cells 
 Using the correct tumor model is essential when researching cancer, and ethical 
considerations limit the ability to test cancer in human subjects. When comparing blood flow to a 
subcutaneous model of prostate cancer cells and blood flow to an orthotopic prostate tumor 
model during exercise in the rat, blood flow to the subcutaneous tumor was decreased by 25% 
during exercise whereas orthotopic prostate tumor flow was increased by 181% during exercise 
(Garcia et al., 2016). Orthotopic tumors are also better predictors of clinical success (Killion et 
al., 1998).  
 A comparison of a subcutaneous and peritoneal injection of colon cancer cells showed 
differences in multiple tissues between groups (Matsuyama et al., 2015). The control group had 
significantly larger gastrocnemius masses compared to both the subcutaneous and peritoneal 
colon cancers. There were also differences between each type of cancer, as the subcutaneous 
model of colon cancer had significantly larger gastrocnemius masses when compared to the 
peritoneal model. Cardiac muscle mass was not different between the control and subcutaneous 
group, however the peritoneal group had significantly reduced cardiac mass compared to both 
the control and subcutaneous group (Matsuyama et al., 2015). Importantly, these inconsistencies 
highlight how essential using the correct tumor model is with cancer research. 
 Within prostate tumor models, AT-1 cells from the Dunning R-3327 strain of prostate 
carcinoma cells tumor cells cultured in RPMI 1640 media with 10% Fetal Bovine Serum, 1% 
penicillin/streptomyocin, 2mM glutamine, and 250 µM dexamethasone in a 37oC incubator have 
been used in past research as a viable model for rat prostate cancer (Dunning, 1963; McCullough 
et al., 2013), producing prostate tumors in rats. These cells mimic the growth patterns of human 
prostate cancer (Isaacs et al., 1978). 
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Chapter 2 - Introduction 
Cancer patients have a reduced maximal exercise capacity (i.e., maximal oxygen 
consumption, VO2max) and report exaggerated levels of fatigue (excessive tiredness) when 
compared to their age-matched healthy counterparts (Curt et al., 2000; Peel et al., 2014). 
Excessive fatigue is experienced by over 50% of cancer patients (Cella et al., 2001; Wagner & 
Cella, 2004; Hofman et al., 2007; Wang et al., 2014; Charalambous & Kouta, 2016) and is 
related to the type of cancer (Birgegård et al., 2005; Hofman et al., 2007; Wang et al., 2014) as 
well as both the type (Hofman et al., 2007; Alibhai et al., 2015) and duration (Wall et al., 2015) 
of treatment. The exaggerated levels of fatigue in cancer patients impair the ability to perform 
activities of daily living which has been shown to lead to a reduced quality of life (Curt et al., 
2000; Morrow et al., 2002; Charalambous & Kouta, 2016). Multiple mechanisms likely 
contribute to the reduced exercise capacity and exaggerated fatigue in cancer patients. For 
example, reductions in cardiac function (Chicco et al., 2005; Springer et al., 2014), anemia 
(Birgegård et al., 2005), reduced cardiac and skeletal muscle mass (i.e., cachexia; Tisdale, 2009; 
Matsuyama et al., 2015; Murphy, 2016), and increased fat mass (Galvão et al., 2008) have all 
been reported in cancer patients. Given the clear link between fatigue and reduced quality of life 
in cancer patients (Curt et. al., 2000), identifying the specific mechanisms that contribute to the 
reduced exercise capacity and exaggerated fatigue would have immense clinical value. One 
specific hindrance, however, to identifying the causes and mechanisms of fatigue in this 
population is that various forms of cancer (Wysong et al., 2011; Xu et al., 2011; Matsuyama et 
al., 2015) and cancer treatments (Arola et al., 2000; Chicco et al., 2005; van Norren et al., 2009) 
by themselves have been shown to produce deleterious physiological effects. 
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 One in five men will be diagnosed with prostate cancer in his lifetime, making prostate 
cancer the most common cancer in men (Siegel et al., 2016). One of the most common 
treatments for prostate cancer is surgical or pharmacological androgen deprivation therapy 
(ADT) which itself has been implicated in multiple undesired side-effects including reduced 
muscle mass and bone density as well as increased fat mass (Cheung et al., 2014; Rhee et al., 
2015; Nelson et al., 2016). These side-effects likely contribute to the fact that prostate cancer 
patients receiving ADT have reduced 6-minute walk test performance and grip strength when 
compared to healthy controls (Alibhai et al., 2015). Furthermore, prostate cancer patients on 
ADT for more than three months have a lower VO2max compared to those on ADT for less than 
three months (Wall et al., 2015). While ADT certainly contributes to the reductions in exercise 
capacity found in prostate cancer patients the effect of the prostate cancer itself may also play a 
role, but this has not been investigated. 
The purpose of this study was to investigate the effect of untreated prostate cancer on 
endurance exercise capacity in an established rat prostate tumor model. We tested the hypothesis 
that time to exhaustion during submaximal treadmill running would be reduced following the 
development of prostate cancer compared to pre-cancer values. Additionally, to examine 
potential mechanisms by which prostate cancer may impact endurance exercise capacity in this 
model, we tested the hypothesis that prostate cancer would reduce cardiac function, cardiac and 
hindlimb skeletal muscle mass, as well as hindlimb skeletal muscle oxidative capacity. 
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Chapter 3 - Methods 
All procedures were approved by the Institutional Animal Care and Use Committee at 
Kansas State University and complied with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals (National Research Council Committee, Washington, D.C., rev. 
2011). Eighteen immunocompetent male Copenhagen rats (COP/CrCrl, Charles River, 
Wilmington, MA) were used. The rats were housed at 23oC using a 6 AM to 6 PM 12-hour light-
dark cycle and provided rat chow and water ad libitum. 
  
  Experimental Protocol 
 All rats were acclimated to treadmill running on a custom built motor driven treadmill for 
approximately five days at 25 m/min at a 10% incline. In order to ensure the rats remained 
untrained, each acclimation lasted <5 minutes. Within three days of the final acclimation, 
endurance exercise capacity was assessed by measuring time to exhaustion during a graded 
submaximal treadmill test according to the methods described in detail by Copp et al. (2009) (see 
below). 
After the initial endurance exercise capacity test, the rats were assigned to either a sham 
or cancer group. At least 48 hours of recovery was given until the sham or cancer surgery was 
performed (see below). Three weeks after surgery, the rats were re-familiarized (~3 times, <5 
min each) to treadmill running and the endurance exercise capacity test was repeated four weeks 
post-surgery. At seven weeks post-surgery, rats were again re-familiarized (~3 times, <5 min 
each) to treadmill running and the final endurance exercise capacity test was completed at eight 
weeks post-surgery. 
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Following the final endurance exercise capacity test, rats were anesthetized (2-3% 
isofluorane O2 balance) and the right carotid artery was isolated and cannulated for the 
advancement of a 2-Fr catheter-tipped pressure transducer (Millar Instruments, Houston, TX) 
into the left ventricle (LV) to measure the rate of LV pressure increase over time 
(Δpressure/Δtime) and the LV end-diastolic pressure (LVEDP). The pressure transducer was then 
withdrawn from the LV and systolic blood pressure was measured when the catheter tip was in 
the aorta. Thereafter the rats were euthanized by a thoracotomy under anesthesia (5% isofluorane 
O2 balance) followed by removal of the heart to verify death. Subsequently, the left 
gastrocnemius, extensor digitorum longus (EDL), and soleus muscles, the heart, as well as a 
portion of the costal diaphragm muscle were dissected and weighed. The wall of the right 
ventricle (RV) was cut away and the RV wall and the LV (along with the intraventricular 
septum) were weighed separately. In addition, red and white portions of the gastrocnemius were 
isolated and dissected. The left femur was also dissected and the length was measured. All 
tissues were frozen at -80oC for future analysis.  
 
  Endurance Exercise Capacity Protocol 
The endurance exercise capacity test consisted of 15 minute stages starting at 25 m/min 
for 15 minutes at a 10% incline. The speed of the treadmill was increased by 5 m/min every 15 
minutes (with the incline held constant) until the rat was unable or unwilling to run. Rats were 
motivated to run with bursts of high-pressure air aimed at the hind legs. An endurance exercise 
capacity test was deemed valid if a marked attenuation of the rat’s righting reflex and/or a 
noticeable change in gait that is indicative of exhaustion prior to termination of the test was 
present (Copp et al., 2009). Time to exhaustion was measured to the nearest second. The work 
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performed (joules) during each test was calculated by multiplying the vertical distance run by the 
rat’s body mass and then dividing by 9.81. No endurance exercise capacity test was repeated 
more than once, and tests were repeated in the same proportion by sham rats and cancer rats. 
Each test was completed between 8 AM and 12 PM by the same investigators in a room with the 
temperature maintained between 21 and 23°C, with no additional fans or cooling devices used. 
During each endurance exercise capacity test the investigators were blinded to the group and 
previous run times of the rat. 
 
  Prostate Cancer Model 
The AT-1 cell line from the Dunning R-3327 strain of Copenhagen rat prostate 
carcinoma cells was used (Dunning, 1963). These cells have a high growth rate, low metastatic 
potential, and are similar to the growth patterns of human prostate cancer (Isaacs et al., 1978). 
The cells were grown in RPMI 1640 media with 10% Fetal Bovine Serum, 1% 
penicillin/streptomyocin, 2 mM glutamine, and 250 µM dexamethasone in a 37oC humidified 
incubator at 5% CO2. When cells reached ~90% confluence, a sample of the cells were counted 
in a hemocytometer, and the rest of the viable cells were used to prepare a tumor cell stock 
solution with Matrigel. Matrigel enhances the chance the cancer cells will form a tumor and 
augments tumor growth (Kleinman & Martin, 2005). This solution was aliquoted into 0.1 mL 
syringes that each contained approximately 105 AT-1 cells. This model has been used previously 
to induce prostate cancer (McCullough et al., 2014; Garcia et al., 2016). 
All procedures were performed under aseptic conditions. Rats were anesthetized (2-4% 
isofluorane O2 balance) and the bladder/prostate complex was exposed through a small incision 
(<2cm) lateral to the midline of the abdomen. The ventral lobe of the prostate in the cancer group 
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were injected with the cell stock solution with cancer cells and 0.1mL of Matrigel using sterile 
insulin syringes (26G). The prostates of the rats in the sham group were injected with 0.1mL of 
Matrigel without cancer cells. Following the surgery, the incision was closed and rats were 
injected with buponorphrine (0.05 mL/kg) and acepromazine (0.04 mL/kg). Post-operative 
monitoring occurred daily for one week.  
 
  Citrate Synthase Activity 
Citrate synthase activity was measured in the red and white portions of the 
gastrocnemius, soleus, and costal diaphragm muscles as a marker of oxidative capacity. The 
muscles were mechanically homogenized and analysis was completed by a spectrophotometer 
using the methods of Srere (1969). Briefly, 15 µl and 30 µl samples were diluted using 210 µl 
and 195 µl of tris buffer, respectively, and 15 µl of acetyl coenzyme A and 30 µl of DTNB were 
added to each sample. All samples were incubated in a spectrophotometer (Fisher Scientific, 
accuSkan GO) for 5 minutes at 30oC. Readings were taken once per minute for five minutes and 
then 35 µl of oxaloacetate was added to all samples and immediately analyzed again. The citrate 
synthase activity was given in µmol/min/g wet weight. If the difference between the 15 µl and 
the 30 µl samples was larger than 15% the sample was re-analyzed until there was less than 15% 
difference.  
 
  Data Analysis 
Statistical analyses were completed in Prism (version 7.0, Graphpad) data analysis 
software. Two-way ANOVAs with SNK post-hoc tests or unpaired t-tests were used to compare 
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group means as appropriate. Pearson Product Moment Correlations and regression analyses were 
used to quantify relationships between variables. Significance was accepted at p < 0.05.  
  
 14 
Chapter 4 - Results 
All eighteen rats completed the experimental protocol. In the cancer group, one rat 
developed an ectopic tumor rather than a prostate tumor and one rat did not develop a tumor. The 
data from these rats are shown in Appendix A but were excluded from the analyses resulting in 
final sample sizes of n = 7 and n = 9 for the sham and cancer groups, respectively. The average 
tumor mass in the cancer group was 9.8 ± 2.6 g (range: 0.2 to 19.5 g).  
For body mass, there was a statistically significant main effect of time (p < 0.001), but 
there was not a statistically significant group effect (p = 0.762) or interaction (p = 0.543, Figure 
1A). Body mass increased significantly in both groups from the initial to the four week test 
(sham: p = 0.045, cancer: p = 0.006) and was further increased at the eight week compared to the 
four week test in the sham group (p = 0.039) but not in the cancer group (p = 0.461). The overall 
increase in body mass over the course of the experimental protocol was not different between 
groups (p = 0.139, Figure 1B). When prostate tumor mass was subtracted from the eight week 
body mass of the rats in the cancer group, however, the overall increase in “non-tumor mass” 
was significantly lower in the cancer group compared to the sham group (p = 0.029, Figure 1C). 
Within the cancer group there was no correlation between tumor mass and eight week body mass 
(r = -0.14, p = 0.725).  
 
  Endurance Exercise Capacity 
For time to exhaustion during the endurance exercise capacity test, there was a 
statistically significant main effect of time (p < 0.001) but there was not a statistically significant 
group effect (p = 0.098) or interaction (p = 0.086, Figure 2A). Time to exhaustion at four weeks 
for the sham group was not different from the initial value (p = 0.971), whereas time to 
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exhaustion at four weeks for the cancer group was significantly reduced from the initial value 
(↓18%, p = 0.027). Time to exhaustion at eight weeks was significantly reduced in both the sham 
and cancer groups from the initial values (p < 0.001 for both). When expressed as the change in 
time to exhaustion from the initial value, the cancer group had a significantly larger reduction 
compared to the sham group at four weeks (p = 0.005, Figure 2B) and at eight weeks (p = 0.038, 
Figure 2C).  
For work performed during the endurance exercise capacity test, there was a statistically 
significant main effect of time (p < 0.001) but there was not a statistically significant group 
effect (p = 0.098, Figure 3A). The interaction between these variables was statistically significant 
(p = 0.037). There was no difference in the work performed between the initial and four week 
tests for either the sham (p = 0.976) or cancer group (p = 0.118). Work performed at eight weeks 
was significantly reduced from the initial values in both the sham and cancer groups (p < 0.001 
for both). When expressed as the change in work from the initial value, the cancer group had a 
significantly larger reduction compared to the sham group at four weeks (p = 0.011, Figure 3B) 
and at eight weeks (p = 0.045, Figure 3C).  
 
  Cardiac Function 
There were no statistically significant differences between the mean values for LVEDP 
(sham: 12 ± 1, cancer: 11 ± 2 mmHg, p = 0.736), LV Δpressure/Δtime (sham: 7614 ± 387, 
cancer: 7038 ± 311 mmHg/s, p = 0.261), or systolic blood pressure (sham: 122 ± 2, cancer: 114 ± 
6 mmHg, p = 0.271) between groups. Within the cancer group, however, tumor mass was 
significantly inversely correlated to LV Δpressure/Δtime (r = -0.71, p = 0.047, Figure 3A) and 
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systolic blood pressure (r = -0.89, p = 0.004, Figure 3B). Tumor mass was not significantly 
correlated to LVEDP (r = -0.14, p = 0.725).  
 
  Cardiac and Skeletal Muscle Mass 
Heart, LV, and gastrocnemius muscle mass were significantly lower in the cancer group 
compared to the sham group (p < 0.05 for all, Table 1). This was the case even when muscle 
mass was normalized to body mass (p < 0.05 for all). RV, EDL, and soleus muscle mass were 
not different between groups. Within the cancer group, tumor mass was significantly inversely 
correlated to heart mass (r = -0.74, p = 0.022, Figure 4A) and LV mass (r = -0.85, p = 0.004, 
Figure 4B). Tumor mass was not significantly correlated to gastrocnemius mass (r = -0.15, p = 
696, Figure 4C). Femur length was not different (p = 0.237) between the sham group (39.4 ± 0.5 
mm) and cancer group (40.6 ± 0.7 mm) indicating there was no difference in the overall growth 
of the rats.  
   
  Citrate Synthase Activity 
 There were no differences in citrate synthase activity between the sham and cancer 
groups for any muscle or muscle part analyzed (Table 2).  
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Table 1. Individual Muscle Mass 
Mean ± SEM. * = statistically significant difference between groups. LV (left ventricle), RV 
(right ventricle), extensor digitorum longus (EDL), BM (body mass).  
 
 
Table 2. Citrate Synthase Activity 
Mean ± SEM. There were no statistically significant differences between groups.  
 
 
 
  
   Sham (n = 7)        Cancer (n = 9) P-Value 
Absolute muscle mass (mg)         
       Heart 820 ± 17  723 ± 30 0.021* 
        LV 601 ± 15  498 ± 20 0.001* 
        RV  219 ± 14  215 ± 18 0.861 
Gastrocnemius 1864 ± 32  1702 ± 35 0.005* 
Soleus  167 ± 8  168 ± 4 0.923 
EDL  158 ± 5  147 ± 4 0.113 
Normalized muscle mass (mg/g)        
       Heart/BM 2.42 ± 0.04  2.19 ± 0.08 0.035* 
               LV/BM 1.77 ± 0.02  1.54 ± 0.05 0.002* 
               RV/BM  0.65 ± 0.04  0.65 ± 0.05 0.960 
Gastrocnemius/BM 5.49 ± 0.07  5.16 ± 0.10 0.022* 
Soleus/BM  0.50 ± 0.01  0.50 ± 0.02 0.731 
Citrate Synthase Activity 
(µmol/min/g) 
  Sham (n = 7)     Cancer (n = 9)       P-Value 
Soleus  19.9 ± 1.7  17.0 ± 1.2 0.719 
Red gastrocnemius  24.1 ± 2.7  25.4 ± 2.1 0.711 
White gastrocnemius 8.5 ± 0.4  7.41 ± 0.3 0.270 
Costal diaphragm  30.7 ± 1.4  20.1 ± 2.5 0.858 
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Figure 1. Body Mass 
Body mass of the sham (n = 7) and cancer (n = 9) groups (A). There was no difference in the 
increase in body mass over the course of the experimental protocol between groups (B). When 
subtracting prostate tumor mass from body mass in the cancer group, the increase in non-tumor 
mass over the course of the experimental protocol was significantly lower in the cancer group 
compared to the sham group (C). Values are mean ± SEM. ‡	  = significantly different from initial 
value, # = significantly different from initial and 4 week values. * = significantly different from 
sham. 
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Figure 2. Time to Exhaustion 
Time to exhaustion during the endurance exercise capacity tests for the sham (n = 7) and cancer 
(n = 9) groups (A). The cancer group had a significantly larger reduction in time to exhaustion 
from the initial value at four weeks (B) and eight weeks (C) compared to the sham group. Values 
are mean ± SEM. ‡ = significantly different from initial value, # = significantly different from 
initial and 4 week values. * = significantly different from sham. 
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Figure 3. Work Performed during Endurance Exercise Capacity Test 
Work performed during the enurance exercise capacity test for the sham (n = 7) and cancer (n = 
9) groups at each time point (A). The cancer group had a significantly larger reduction in work 
performed from the initial value at four weeks (B) and eight weeks (C) compared to the sham 
group. Values are mean ± SEM. ‡	  = significantly different from initial value, # = significantly 
different from initial and 4 week values, * = significantly different from sham. 
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Figure 4. Correlations between Tumor Mass and Indexes of Cardiac Function 
Within the cancer group (n = 9), tumor mass was significantly inversely correlated to LV 
Δpressure/Δtime (A) and systolic blood pressure (B). The open circles represent the mean and 
SEM of the sham group. The closed circles represent individual data from the cancer group. 
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Figure 5. Correlations between Tumor Mass and Select Muscle Masses 
Within the cancer group (n = 9), tumor mass was significantly inversely correlated to heart mass 
(A) and left ventricle (LV) mass (B), but not gastrocnemius mass (C). The open circles represent 
the mean and SEM of the sham group. The closed circles represent individual data from the 
cancer group. 
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Chapter 5 - Discussion 
 Consistent with our hypothesis we found that endurance exercise capacity was reduced in 
rats with prostate cancer, and this reduction was greater than that observed in rats without 
prostate cancer. Additionally, we found that the development of prostate cancer significantly 
reduced heart, LV, and gastrocnemius muscle mass in the cancer group compared to the sham 
group. In contrast, the development of prostate cancer did not reduce citrate synthase activity, an 
index of oxidative capacity, in the gastrocnemius, soleus, or costal diaphragm muscles. These 
findings are important because they are the first to show that prostate cancer itself reduces 
endurance exercise capacity. 
We measured time to exhaustion using a standardized submaximal treadmill running 
protocol which has been shown to be reproducible within-rat for up to five weeks (Copp et al., 
2009). Unexpectedly, we found that time to exhaustion during the eight week test was decreased 
compared to the four week test in both the sham (↓32%) and cancer groups (↓45%). We 
calculated the work performed during the treadmill test to determine if the slightly greater 
increase in body mass could account for the reduced time to exhaustion in the sham group. That 
was not the case, however, because work performed was also reduced from eight weeks versus 
four weeks in both the sham (↓30%) and cancer (↓46%) groups. Because both the time to 
exhaustion and work performed during the endurance test were reduced from four weeks to eight 
weeks in the sham group, we cannot attribute the reductions in time to exhaustion and worked 
performed during this period in the cancer group entirely to the effects of prostate cancer. It 
appears, therefore, that the effect of prostate cancer on time to exhaustion and work performed in 
our study occurred primarily within the first four weeks following surgery.  
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The reason for the reduction in time to exhaustion and work performed in the sham group 
is unknown. A “learning” effect may have occurred in both groups following the second (or third 
in cases where repeated tests were necessary) endurance exercise tests such that the rats were not 
as motivated to run once sensations of fatigue were perceived. Regardless of the reason time to 
exhaustion and work performed during the endurance exercise tests decreased from eight weeks 
compared to four weeks in the sham group, the overall reductions in both time to exhaustion and 
work performed were significantly greater in the cancer group compared to the sham group. 
Importantly, the greater reductions in time to exhaustion and work performed in the cancer group 
are unlikely to be attribuatble to reductions in cage activity (and therefore deconditioning) 
because citrate synthase activity of the select hindlimb skeletal muscles investigated was not 
different between groups. If the development of prostate cancer had led to reduced spontaneous 
cage activity, we would have expected to see lower skeletal muscle citrate synthase activity 
levels in the cancer group. 
Stroke volume is determined by the preload of the LV (LVEDP), afterload on the heart 
(systolic BP), and the contractility of the LV (LV Δpressure/Δtime). While we did not find any 
statistical differences between group means of these indexes in the present study, we did find that 
within the cancer group systolic BP and LV Δpressure/Δtime were significantly inversely 
correlated to tumor mass. Those inverse correlations between tumor mass and systolic BP and 
LV Δpressure/Δtime were found when the rats were anesthetized and the heart was not stressed 
which is consistent with the study of Springer et al. (2014) who found that stroke volume was 
reduced in a rat model of liver cancer compared to a sham group at rest. In our study, the fact 
that LV contractility was inversely correlated with tumor mass suggests to us that a reduced 
stroke volume likely contributed to the greater reductions in exercise capacity in the cancer 
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group compared to the sham group, particularly in the rats with the largest tumors. Future studies 
which examine the effects of prostate cancer on indexes of stroke volume during exercise are 
warranted.  
Cachexia is defined clinically as a weight loss of at least 5% that is not due to edema 
occurring within a period of 12 months or less that is due to an underlying disease including 
cancer (Evans et al., 2008) and cachexia has been estimated to affect 50-80% of cancer patients 
(Argilés et al., 2014). In our study we found that heart, LV, and gastrocnemius muscle mass 
were lower in the cancer group compared to the sham group and this was true even when 
normalized to body mass (Table 1). Femur lengths were not different between groups, however, 
which suggests that prostate cancer did not affect the overall growth rate of the rats in the cancer 
group. Because body mass increased over the duration of the eight week protocol in both the 
cancer and sham groups we do not know if the lower heart, LV and gastrocnemius muscle 
masses in the cancer group reflect a true cachexia (i.e., a loss) or a growth retardation. 
Regardless, cachexia reflects an imbalance between the rate of protein synthesis and degradation 
(Murphy, 2016) and the lower cardiac and skeletal muscle mass found in our study indicates that 
such an imbalance existed within the cancer group. 
We found that gastrocnemius muscle mass, but not soleus or EDL muscle mass, was 
lower in the cancer group compared to the sham group. The lower gastrocnemius mass in the 
cancer group compared to the sham group is similar to the finding of a Matsuyama et al. (2015) 
who reported lower gastrocnemius muscle mass in a murine model of colon cancer compared to 
control. Our finding that EDL mass was not different between groups is inconsistent with the 
finding of Gorselink et al. (2009) who reported that EDL mass was lower in tumor-bearing mice 
compared to non-tumor bearing mice. Taken together, these findings indicate that the type of 
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cancer, the host species, and/or muscle fiber-type composition may influence the presence of 
skeletal muscle cachexia. Our finding that heart and LV mass were lower in the cancer group 
compared to the sham group is consistent with studies that have reported lower heart mass in 
murine models of colon cancer (Matsuyama et al., 2015) and liver cancer (Springer et al., 2014) 
as well as in a subcutaneous colon cancer model (Wysong et al., 2011). The fact that 
gastrocnemius mass was ~9% lower whereas LV mass was ~15% lower in the cancer group 
compared to the sham group in our study was surprising given the relative lack of information 
regarding the effects of various forms of cancer on cardiac cachexia compared to skeletal muscle 
cachexia (Murphy, 2016). Springer et al. (2014) found that cardiac muscle specifically was more 
impacted by catabolic stimuli than total body mass or total lean mass in a rat model of liver 
cancer. The significant inverse correlation between cardiac mass and tumor mass but not 
gastrocnemius mass and tumor mass in our study further supports the notion that prostate cancer 
had a greater effect on cardiac muscle mass than skeletal muscle mass. Despite this difference, 
however, the reduced gastrocnemius mass likely contributed to the reduced exercise capacity in 
the cancer group because more work per unit of muscle (thus increased recruitment) was 
performed in order for the rat to keep pace with the inclined treadmill. The lower heart and LV 
mass also likely contributed to the attenuated exercise capacity in the cancer group because a 
reduction in LV mass would result in a reduced stroke volume and therefore cardiac output 
during exercise. 
There are two limitations of our study. First, the greatest effect of prostate cancer on 
endurance exercise capacity occurred within the first four weeks following surgery whereas the 
measurement of tumor, skeletal muscle and cardiac muscle mass was performed eight weeks 
following surgery. We chose eight weeks for the length of the study to ensure the rats would 
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develop substantial tumors. Valuable information would be gained from repeating this study and 
determining the effect of prostate cancer on skeletal and cardiac muscle mass four weeks 
following surgery. Second, we did not measure food consumption. The development of liver 
cancer has been shown reduce food intake compared to control (Springer et al., 2014). In our 
study a reduction in food intake may have contributed to reduced protein synthesis, and therefore 
reduced cardiac and skeletal muscle mass in the cancer group compared to the sham group. 
However, as stated above the fact that femur length was not different between groups indicates 
that the overall growth rate of the cancer group was similar to the sham group and that the lower 
cardiac and skeletal muscle masses reflects an effect of prostate cancer itself. 
In summary, endurance exercise capacity was reduced in rats with untreated prostate 
cancer to a greater extent than it was reduced in sham operated rats. Moreover, there were 
significant reductions in heart and LV mass in the cancer group compared to the sham group; 
within the cancer group, heart and LV mass were inversely correlated to tumor mass. The 
significant reduction in gastrocnemius muscle mass was not significantly inversely correlated 
with tumor mass. Although we did not investigate the mechanisms which specifically 
contributed to the reduced endurance exercise capacity in rats with prostate cancer the reduced 
cardiac and skeletal muscle mass likely contributed. Our findings have important implications 
for patients with prostate cancer given that the bulk of the available literature has focused on the 
effects of prostate cancer treatment (namely ADT) and its role in the exaggerated fatigue and 
reduced exercise capacity in this population. 
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Appendix A - Data for Rats Excluded from Final Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left ventricle (LV), right ventricle (RV), extensor digitorum longus (EDL), body mass (BM). 
 
  No Tumor Ectopic Tumor 
Body mass (g)   
 Initial body mass 282 269 
 8 week body mass 335 331 
Endurance exercise capacity    
 Initial time (min) 35.62 34.45 
 4 week time (min) 23.22 29.77 
 8 week time (min) 27.15 26.17 
 Δ pre-test 8 week time (min) -8.47 -8.28 
 Initial work (joules) 3.03 2.74 
 4 week work (joules) 2.50 2.02 
 8 week work (joules) 2.40 2.53 
 Δ Initial 8 week work (joules) -0.63 -0.21 
Tissue mass (mg)   
 Tumor mass N/A 2.1 
 Heart 819 761 
         LV 595 590 
         RV 171 224 
 Soleus 162 159 
 EDL 150 155 
 Gastrocnemius 1783 1834 
Citrate synthase activity (µmol/min/g)  
 Soleus 22.1 17.5 
 Red gastrocnemius 29.5 29.1 
 White gastrocnemius 10.1 8.4 
 Costal diaphragm 30.3 34.8 
